MCID: BRN022
MIFTS: 60

Bronchiectasis

Categories: Genetic diseases, Respiratory diseases

Aliases & Classifications for Bronchiectasis

MalaCards integrated aliases for Bronchiectasis:

Name: Bronchiectasis 12 75 29 55 6 44 15 63 72 33
Polynesian Bronchiectasis 12
Kartagener Syndrome 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9563
ICD9CM 35 494
MeSH 44 D001987
NCIt 50 C84475
SNOMED-CT 68 12295008
ICD10 33 J47 J47.9
UMLS 72 C0006267 C0022521

Summaries for Bronchiectasis

PubMed Health : 63 About bronchiectasis: Bronchiectasis (brong-ke-EK-tah-sis) is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of your lungs. Bronchiectasis often is caused by an infection or other condition that injures the walls of the airways or prevents the airways from clearing mucus. Mucus is a slimy substance. It helps remove inhaled dust, bacteria, and other small particles from the airways. In bronchiectasis, your airways slowly lose their ability to clear out mucus. The mucus builds up, and bacteria begin to grow. This leads to repeated, serious lung infections. Each infection causes more damage to the airways. Over time, the airways can't properly move air in and out of the lungs. As a result, the body's vital organs might not get enough oxygen. Bronchiectasis can lead to serious health problems, such as respiratory failure, atelectasis (at-eh-LEK-tah-sis), and heart failure.

MalaCards based summary : Bronchiectasis, also known as polynesian bronchiectasis, is related to bronchiectasis with or without elevated sweat chloride 1 and idiopathic bronchiectasis, and has symptoms including headache An important gene associated with Bronchiectasis is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways are Innate Immune System and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and neutrophil, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A bronchial disease that is a chronic inflammatory condition of one or more bronchi or bronchioles marked by dilatation and loss of elasticity of the walls resulting from damage to the airway wall leading to the formation of small sacs on the bronchial wall and impairment of cilia mobility in the lung. Inflammation of the bronchial wall increases mucus secretion which serves as a breeding ground for bacteria. Bronchiectasis is caused by repeated respiratory infections, immune deficiency disorders, hereditary disorders (cystic fibrosis or primary ciliary dyskinesia), mechanical factors (inhaled object or a lung tumor) or inhaling toxic substances.

Wikipedia : 75 Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung.... more...

Related Diseases for Bronchiectasis

Diseases in the Bronchiectasis family:

Bronchiectasis 1 Bronchiectasis 2
Bronchiectasis 3

Diseases related to Bronchiectasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 530)
# Related Disease Score Top Affiliating Genes
1 bronchiectasis with or without elevated sweat chloride 1 35.0 SCNN1B CFTR
2 idiopathic bronchiectasis 34.2 SCNN1G SCNN1B SCNN1A CFTR
3 nontuberculous mycobacterial lung disease 32.4 TLR2 CFTR
4 haemophilus influenzae 31.3 TLR2 CXCL8
5 respiratory failure 31.1 SERPINA1 ELANE CXCL8
6 bronchitis 30.8 SERPINA1 MPO ELANE CXCL8 CFTR
7 pulmonary emphysema 30.7 SERPINA1 MMP8 ELANE
8 aspergillosis 30.5 TLR2 MBL2 ELANE CFTR
9 ulcerative colitis 30.4 MPO CXCL8 BPI
10 mycobacterium kansasii 30.3 TLR2 CXCL8
11 anca-associated vasculitis 30.2 SERPINA1 MPO
12 mycobacterium abscessus 30.1 TLR2 SERPINA1 CXCL8 CFTR
13 mycobacterium chelonae 30.1 TLR2 CXCL8
14 otitis media 30.0 TLR2 MBL2 CXCL8
15 crescentic glomerulonephritis 29.8 MPO CTSG BPI
16 proteasome-associated autoinflammatory syndrome 1 29.7 TLR2 MPO ELANE CXCL8
17 pneumonia 29.6 TLR2 MPO MBL2 ELANE CXCL8
18 vasculitis 29.6 SERPINA1 MPO ELANE CTSG BPI
19 sclerosing cholangitis 29.5 MPO CTSG CFTR BPI
20 inflammatory bowel disease 29.4 TLR2 STAT1 MPO CXCL8
21 invasive aspergillosis 29.4 TLR2 MBL2 CXCL8
22 alpha-1-antitrypsin deficiency 29.4 SERPINA3 SERPINA1 ELANE CXCL8 BPI
23 cystic fibrosis 29.2 SERPINA1 SCNN1G SCNN1B SCNN1A MPO MBL2
24 bacterial infectious disease 29.0 TLR2 MBL2 ELANE CXCL8 CFTR BPI
25 pulmonary disease, chronic obstructive 28.8 TLR2 SERPINA3 SERPINA1 MPO ELANE CXCL8
26 lung disease 28.4 TLR2 SERPINA1 MPO MMP8 MBL2 ELANE
27 granulomatosis with polyangiitis 28.1 TLR2 SERPINA1 MPO ELANE CTSG BPI
28 systemic lupus erythematosus 27.9 TLR2 STAT1 MPO MBL2 ELANE CTSG
29 bronchiectasis with or without elevated sweat chloride 3 12.6
30 bronchiectasis with or without elevated sweat chloride 2 12.5
31 bronchiectasis 2 12.5
32 bronchiectasis 1 12.5
33 bronchiectasis 3 12.5
34 ciliary dyskinesia-bronchiectasis 12.3
35 bronchiectasis oligospermia 12.1
36 ciliary dyskinesia, primary, 1 12.1
37 primary ciliary dyskinesia 12.0
38 kartagener syndrome 12.0
39 panbronchiolitis, diffuse 11.5
40 yellow nail syndrome 11.5
41 young syndrome 11.5
42 bronchial disease 11.4
43 mounier-kuhn syndrome 11.4
44 tracheobronchomegaly 11.3
45 bare lymphocyte syndrome, type i 11.3
46 ciliary dyskinesia, primary, 3 11.3
47 ciliary dyskinesia, primary, 17 11.3
48 immunodeficiency 12 11.3
49 ciliary dyskinesia, primary, 25 11.2
50 ciliary dyskinesia, primary, 26 11.2

Comorbidity relations with Bronchiectasis via Phenotypic Disease Network (PDN): (show all 20)


Agammaglobulinemia, X-Linked Anxiety
Aspergillosis Bronchitis
Bronchopneumonia Chronic Pulmonary Heart Disease
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hypothyroidism Idiopathic Interstitial Pneumonia
Lung Abscess Mitral Valve Disease
Osteoporosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Pulmonary Tuberculosis
Respiratory Failure Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Bronchiectasis:



Diseases related to Bronchiectasis

Symptoms & Phenotypes for Bronchiectasis

UMLS symptoms related to Bronchiectasis:


headache

MGI Mouse Phenotypes related to Bronchiectasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CFTR CTSG DNAH5 DNAI1 ELANE MBL2
2 immune system MP:0005387 9.96 CFTR CTSG DNAH5 DNAI1 ELANE MBL2
3 digestive/alimentary MP:0005381 9.91 CFTR DNAH5 SCNN1A SCNN1B SCNN1G STAT1
4 mortality/aging MP:0010768 9.9 CFTR CTSG DNAH5 DNAI1 ELANE MPO
5 normal MP:0002873 9.56 CFTR CTSG ELANE SCNN1A SCNN1B SCNN1G
6 respiratory system MP:0005388 9.17 CFTR DNAH5 DNAI1 SCNN1A SCNN1B SCNN1G

Drugs & Therapeutics for Bronchiectasis

PubMed Health treatment related to Bronchiectasis: 63

Bronchiectasis often is treated with medicines, hydration, and chest physical therapy (CPT). Your doctor may recommend surgery if the bronchiectasis is isolated to a section of lung or you have a lot of bleeding. If the bronchiectasis is widespread and causing respiratory failure, your doctor may recommend oxygen therapy. The goals of treatment are to: Treat any underlying conditions and lung infections.Remove mucus (a slimy substance) from your lungs. Maintaining good hydration helps with mucus removal.Prevent complications. Early diagnosis and treatment of the underlying cause of bronchiectasis may help prevent further lung damage.  In addition, any disease associated with the bronchiectasis, such as cystic fibrosis or immunodeficiency, also should be treated.

Drugs for Bronchiectasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 4 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
3
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
4
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
5
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8
Metronidazole Approved Phase 4 443-48-1 4173
9
Vancomycin Approved Phase 4 1404-90-6 441141 14969
10
Theophylline Approved Phase 4 58-55-9 2153
11
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
12
Atorvastatin Approved Phase 4 134523-00-5 60823
13
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
14
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 64778 441130
15
Budesonide Approved Phase 4 51333-22-3 63006 5281004
16
Ivacaftor Approved Phase 4 873054-44-5 16220172
17
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
18
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
19
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
21
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
22 Topoisomerase Inhibitors Phase 4
23 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
24 Contraceptives, Oral Phase 4
25 Contraceptive Agents Phase 4
26 Contraceptives, Oral, Combined Phase 4
27 Norgestimate, ethinyl estradiol drug combination Phase 4
28 Estradiol 3-benzoate Phase 4
29 Estradiol 17 beta-cypionate Phase 4
30 Micronutrients Phase 4
31 Trace Elements Phase 4
32 Vitamins Phase 4
33 Nutrients Phase 4
34 Vitamin D2 Phase 4
35 Ergocalciferols Phase 4
36 Calcium, Dietary Phase 4
37 Calciferol Phase 4
38 Bone Density Conservation Agents Phase 4
39 Renal Agents Phase 4
40 Antiprotozoal Agents Phase 4
41 Antiparasitic Agents Phase 4
42 Anti-Infective Agents, Urinary Phase 4
43 Autonomic Agents Phase 4
44 Anti-Asthmatic Agents Phase 4
45 Bronchodilator Agents Phase 4
46 Purinergic P1 Receptor Antagonists Phase 4
47 Phosphodiesterase Inhibitors Phase 4
48 Gentamicins Phase 4
49 Adjuvants, Immunologic Phase 4
50 Broncho-Vaxom Phase 4

Interventional clinical trials:

(show top 50) (show all 338)
# Name Status NCT ID Phase Drugs
1 A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With Bronchiectasis Unknown status NCT01677403 Phase 4 Tobramycin;Saline
2 Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis: a Double-blind Randomised Controlled Trial Unknown status NCT02507843 Phase 4 Cholecalciferol;Placebo
3 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
4 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
5 The Polysaccharide Antibody Response Study: Typhim Vi Response and Allohemagglutinins Versus Pneumovax 23 Vaccine Response in the Diagnosis of Specific Polysaccharide Antibody Deficiency Unknown status NCT02429531 Phase 4
6 Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration Factors Unknown status NCT00752947 Phase 4 moxifloxacin;levofloxacin;metronidazole
7 Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia: A Pilot Study Unknown status NCT02478710 Phase 4 Aerosolized Tobramycin or Vancomycin;Aerosolized Placebo
8 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
9 Clinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) Bronchiectasis Completed NCT01684683 Phase 4 Theophylline;Placebo(for Theophylline)
10 Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis Completed NCT00749866 Phase 4 Gentamicin;Saline
11 To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients Completed NCT01968421 Phase 4 OM-85
12 The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Completed NCT01769898 Phase 4 Formoterol-budesonide;Theophylline;Placebo
13 A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Completed NCT02081963 Phase 4 Amikacin;Normal saline
14 Efficacy of Azithromycin in Treatment of Bronchiectasis Completed NCT02107274 Phase 4 Azithromycin;Placebo for Azithromycin
15 Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis With Airway Limitation: a Prospective Study Completed NCT02782312 Phase 4 ICS+LABA
16 Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis? Completed NCT00816309 Phase 4
17 A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Completed NCT01299181 Phase 4 Atorvastatin
18 A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in Patients With Pseudomonas Aeruginosa Completed NCT01299194 Phase 4 ATORVASTATIN
19 Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis Completed NCT00868075 Phase 4
20 Effectiveness and Safety of Inhaling Hypertonic Saline in the Functional Exercise Capacity of Patients With Chronic Obstructive Pulmonary Disease: a Randomized Trial Completed NCT00639236 Phase 4
21 Multicenter Controlled Trial on Efficacy of TPEP Device in Adult Patients With Chronic Hypersecretion Completed NCT00700388 Phase 4
22 An Investigation Into the Mechanisms of Action of a Combined Long Acting Beta Agonist/Inhaled Corticosteroid (Seretide 500 Accuhaler) on the Bacterial Colonisation, Immunology and Inflammation of Patients With Chronic Obstructive Pulmonary Disease Completed NCT00974805 Phase 4 Seretide 500 Accuhaler
23 Nebulized Hypertonic Saline for Acute Bronchiolitis in the Emergency Department Completed NCT01247064 Phase 4 Nebulized 3% saline;Nebulized 0.9% Normal Saline
24 Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis:An Open-label Randomized Parallel Controlled Study Recruiting NCT02509091 Phase 4 Bronchoalveolar Lavage and Local Amikacin Injection
25 The Study on the Effects of Traditional Chinese Medicine Through a Series of N-of-1 Trials Based on the Mathematical Model of "Carryover Effect" Recruiting NCT03147443 Phase 4 Individualized Decoction;placebo;Tested drug minus heat-clearing herbs
26 Bacterial Load Guided Therapy for Severe Exacerbations of Bronchiectasis Requiring IntraVenous Antibiotic Therapy- BLT Br IV Study Active, not recruiting NCT02047773 Phase 4 Colomycin;Meropenem
27 Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections. Active, not recruiting NCT01735084 Phase 4
28 The Comparisons of the Efficacy and Safety of Inhaled LAMA or LAMA+LABA or ICS+LABA for Patients in COPD C Group With Bronchiectasis Enrolling by invitation NCT02546297 Phase 4 Symbicort;Spiriva
29 An Open Label Study to Investigate the Role of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis With CFTR Dysfunction Not yet recruiting NCT03251911 Phase 4 Ivacaftor (VX-770)
30 Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis- A Proof of Concept Study Not yet recruiting NCT03737617 Phase 4 Cuvitru 20 % Injectable Solution
31 "Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use: A Randomized Controlled Trial" Not yet recruiting NCT03364218 Phase 4 N acetyl cysteine nebulized
32 Open Trial With Randomized Withdrawal of Treatment, to Evaluate the Efficacy of Azithromycin in the Treatment of Children With Non Cystic Fibrosis Bronchiectasis ( AZI-STOP Study ) Unknown status NCT02531984 Phase 3 Azithromycin
33 Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment Unknown status NCT00415350 Phase 3 Azithromycin
34 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
35 An Open Label Trial of Azithromycin in Chronic Productive Cough Unknown status NCT02196493 Phase 3 Azithromycin
36 Randomised Double Blind Placebo Controlled Trial of Effects of Long Term Low Dose Oral Erythromycin Therapy in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT00147667 Phase 2, Phase 3 Erythromycin
37 Intrapleural Minocycline After Simple Aspiration for the Prevention of Primary Spontaneous Pneumothorax: A Randomized Trial Unknown status NCT00418392 Phase 3
38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension Completed NCT02104245 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
39 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3) Completed NCT01515007 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
40 A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis. Completed NCT00277537 Phase 3 Mannitol;placebo
41 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2) Completed NCT01314716 Phase 3 AZLI;Placebo
42 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection Completed NCT01313624 Phase 3 AZLI;Placebo
43 : A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis. Completed NCT00669331 Phase 3 Inhaled mannitol;Matched control
44 Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis. Completed NCT02106832 Phase 3 Ciprofloxacin (BAYQ3939) dry powder for inhalation;Ciprofloxacin (BAYQ3939) dry powder for inhalation;Placebo;Placebo
45 "A Prospective, Cross-over Randomized Trial to Assess the Efficacy and Safety of Mechanical Percussor "LEGA" Compared With Conventional Chest Physiotherapy in Adults With Chronic Bronchiectasis or Chronic Obstructive Pulmonary Disease (COPD Completed NCT01480882 Phase 2, Phase 3
46 Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis. Completed NCT01764841 Phase 3 Ciprofloxacin DPI (BAYQ3939);Placebo
47 The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non-cystic Fibrosis Bronchiectasis. Completed NCT00484263 Phase 3 Hypertonic saline 6% -
48 Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study Completed NCT00380315 Phase 3 AG1321001(drug)
49 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
50 An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD) Completed NCT01814800 Phase 3

Search NIH Clinical Center for Bronchiectasis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetylcysteine
Amoxicillin

Cochrane evidence based reviews: bronchiectasis

Genetic Tests for Bronchiectasis

Genetic tests related to Bronchiectasis:

# Genetic test Affiliating Genes
1 Bronchiectasis 29

Anatomical Context for Bronchiectasis

MalaCards organs/tissues related to Bronchiectasis:

41
Lung, Testes, Neutrophil, Heart, Colon, Liver, Bone

Publications for Bronchiectasis

Articles related to Bronchiectasis:

(show top 50) (show all 8706)
# Title Authors PMID Year
1
Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. 9 38
20167849 2010
2
Allergic bronchopulmonary aspergillosis. 9 38
20463254 2010
3
Novel cftr gene sequence variation in Serbian patient with idiopathic disseminated bronchiectasis. 9 38
20334484 2010
4
Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. 9 38
19616787 2009
5
Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis. 9 38
19555716 2009
6
Stable bronchiectasis is associated with low serum L-ficolin concentrations. 9 38
20298369 2009
7
Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. 9 38
19138237 2008
8
Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. 9 38
18978467 2008
9
TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. 9 38
18684966 2008
10
Could a defective epithelial sodium channel lead to bronchiectasis. 9 38
18507830 2008
11
Airway inflammation in cystic fibrosis. 9 38
18252915 2008
12
Lack of association between matrix metalloproteinase 8 promoter polymorphism and bronchiectasis in Koreans. 9 38
17728507 2007
13
The role of TAP1 and TAP2 gene polymorphism in idiopathic bronchiectasis in children. 9 38
17245734 2007
14
Toll-like receptors 2 and 4 and innate immunity in neutrophilic asthma and idiopathic bronchiectasis. 9 38
17329561 2007
15
CD4/CD8 ratio and cytokine levels of the BAL fluid in patients with bronchiectasis caused by sulfur mustard gas inhalation. 9 38
17224076 2007
16
Lack of association between the microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene and bronchiectasis among Koreans. 9 38
17207025 2007
17
Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. 9 38
17035430 2006
18
Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: a pilot study. 9 38
16678503 2006
19
Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. 9 38
16476120 2006
20
Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. 9 38
16297171 2005
21
[Bronchiectasis worsening by p-ANCA (bactericidal/permeability-increasing protein) positive vasculitis. A case report and review of the literature]. 9 38
16610259 2005
22
Chronic Burkholderia multivorans bronchial infection in a non-cystic fibrosis individual with mannose binding lectin deficiency. 9 38
15681508 2005
23
CFTR mutations and polymorphisms in adults with disseminated bronchiectasis: a controversial issue. 9 38
15618592 2005
24
Indirect CFTR mutation identification by PCR/OLA anomalous electropherograms. 9 38
16379540 2005
25
Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good. 9 38
15478278 2004
26
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. 9 38
15130905 2004
27
Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations? 9 38
15151509 2004
28
Atypical sinusitis in adults must lead to looking for cystic fibrosis and primary ciliary dyskinesia. 9 38
15126740 2004
29
Role of CFTR mutations in adult bronchiectasis. 9 38
15047968 2004
30
[A case of pleural effusion associated with allergic bronchopulmonary aspergillosis during a relapse of the disease]. 9 38
14727554 2003
31
The phenotypic consequences of CFTR mutations. 9 38
12940920 2003
32
Isolated idiopathic chronic pancreatitis associated with a compound heterozygosity for two mutations of the CFTR gene. 9 38
14586256 2003
33
Sputum sol neutrophil elastase activity in bronchiectasis: differential modulation by syndecan-1. 9 38
12702549 2003
34
High frequency of T9 and CFTR mutations in children with idiopathic bronchiectasis. 9 38
12843327 2003
35
[Molecular genetics principles in cystic fibrosis. An example of genetic illness in pneumology]. 9 38
14567084 2003
36
Lymphocytes in allergic bronchopulmonary aspergillosis. 9 38
12700106 2003
37
A preliminary assessment of alpha-1 antitrypsin S and Z deficiency allele frequencies in common variable immunodeficiency patients with and without bronchiectasis. 9 38
12452840 2002
38
Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis. 9 38
15463812 2002
39
Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. 9 38
11877474 2002
40
Allergic bronchopulmonary aspergillosis: a rare cause of pleural effusion. 9 38
11844130 2001
41
Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. 9 38
11719301 2001
42
Diagnosis and treatment of allergic bronchopulmonary aspergillosis. 9 38
11560305 2001
43
Recent advances in cystic fibrosis. 9 38
11420207 2001
44
In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. 9 38
11400153 2001
45
CFTR gene mutations--including three novel nucleotide substitutions--and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. 9 38
11354633 2001
46
Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. 9 38
11120902 2001
47
Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. 9 38
11292112 2000
48
Immunology of allergic bronchopulmonary aspergillosis. 9 38
15597669 2000
49
Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. 9 38
10669684 2000
50
Sputum elastase in steady-state bronchiectasis. 9 38
10669685 2000

Variations for Bronchiectasis

ClinVar genetic disease variations for Bronchiectasis:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1): c.1154C> T (p.Thr385Met) single nucleotide variant Pathogenic rs587777630 2:191851647-191851647 2:190986921-190986921
2 USP11 NM_004651.3(USP11): c.1599G> A (p.Thr533=) single nucleotide variant Likely pathogenic X:47101903-47101903 X:47242504-47242504
3 SCNN1A NM_001038.6(SCNN1A): c.1427G> A (p.Arg476Gln) single nucleotide variant Uncertain significance 12:6458505-6458505 12:6349339-6349339

Expression for Bronchiectasis

Search GEO for disease gene expression data for Bronchiectasis.

Pathways for Bronchiectasis

Pathways related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 TLR2 STAT1 SERPINA3 SERPINA1 MPO MMP8
2
Show member pathways
12.42 SCNN1G SCNN1B SCNN1A CFTR
3
Show member pathways
12.07 TLR2 ELANE CTSG BPI
4
Show member pathways
11.91 TLR2 STAT1 CXCL8 CFTR
5
Show member pathways
11.84 TLR2 STAT1 CXCL8 CFTR
6
Show member pathways
11.76 SCNN1G SCNN1B SCNN1A
7
Show member pathways
11.65 MMP8 ELANE CTSG
8 11.64 TLR2 CXCL8 CTSG
9 11 SCNN1G SCNN1B SCNN1A
10 10.8 SCNN1G SCNN1B SCNN1A CFTR
11 10.79 STAT1 SERPINA3
12 10.79 SCNN1G SCNN1B SCNN1A
13 10.04 SCNN1G SCNN1B SCNN1A CFTR

GO Terms for Bronchiectasis

Cellular components related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 SERPINA3 SERPINA1 SCNN1G SCNN1B SCNN1A MPO
2 cell surface GO:0009986 9.85 TLR2 MBL2 ELANE CTSG CFTR
3 extracellular space GO:0005615 9.81 SERPINA3 SERPINA1 MPO MMP8 MBL2 ELANE
4 apical plasma membrane GO:0016324 9.8 SCNN1G SCNN1B SCNN1A CFTR
5 secretory granule GO:0030141 9.65 MPO ELANE CTSG
6 collagen-containing extracellular matrix GO:0062023 9.65 SERPINA3 SERPINA1 MMP8 ELANE CTSG
7 specific granule lumen GO:0035580 9.58 MMP8 ELANE BPI
8 outer dynein arm GO:0036157 9.43 DNAI1 DNAH5
9 sodium channel complex GO:0034706 9.13 SCNN1G SCNN1B SCNN1A
10 azurophil granule lumen GO:0035578 9.02 SERPINA3 MPO ELANE CTSG BPI
11 extracellular region GO:0005576 10.02 SERPINA3 SERPINA1 MPO MMP8 MBL2 ELANE

Biological processes related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.78 TLR2 MPO ELANE CTSG
2 sodium ion transport GO:0006814 9.76 SCNN1G SCNN1B SCNN1A
3 neutrophil degranulation GO:0043312 9.76 TLR2 SERPINA3 SERPINA1 MPO MMP8 ELANE
4 defense response to Gram-positive bacterium GO:0050830 9.73 TLR2 MBL2 CTSG
5 defense response to bacterium GO:0042742 9.72 MPO MBL2 ELANE CTSG BPI
6 sodium ion transmembrane transport GO:0035725 9.7 SCNN1G SCNN1B SCNN1A
7 extracellular matrix disassembly GO:0022617 9.69 MMP8 ELANE CTSG
8 antimicrobial humoral response GO:0019730 9.67 ELANE CTSG BPI
9 sensory perception of taste GO:0050909 9.61 SCNN1G SCNN1B SCNN1A
10 outer dynein arm assembly GO:0036158 9.58 DNAI1 DNAH5
11 acute-phase response GO:0006953 9.58 SERPINA3 SERPINA1 MBL2
12 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.57 TLR2 STAT1
13 response to molecule of bacterial origin GO:0002237 9.55 TLR2 CXCL8
14 positive regulation of immune response GO:0050778 9.54 ELANE CTSG
15 defense response to fungus GO:0050832 9.54 MPO ELANE CTSG
16 response to yeast GO:0001878 9.46 MPO ELANE
17 sodium ion homeostasis GO:0055078 9.43 SCNN1G SCNN1B SCNN1A
18 negative regulation of growth of symbiont in host GO:0044130 9.26 MPO MBL2 ELANE CTSG
19 multicellular organismal water homeostasis GO:0050891 8.92 SCNN1G SCNN1B SCNN1A CFTR

Molecular functions related to Bronchiectasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.33 MMP8 ELANE CTSG
2 WW domain binding GO:0050699 9.13 SCNN1G SCNN1B SCNN1A
3 ligand-gated sodium channel activity GO:0015280 8.8 SCNN1G SCNN1B SCNN1A

Sources for Bronchiectasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....